PTC Therapeutics Q2 revenue $214M (+29% YoY); raises full-year guidance to $940M-$1.0B

PTC THERAPEUTICS, INC.

2023-Q2 EPS reported -$4.55 revenue$434,190,000

Total revenue $213.8M vs $165.5M Q2 2022; DMD franchise $162M (+21%).
Translarna net revenue $96.5M; Emflaza $65.7M; Evrysdi royalties $36.9M.
Sepiapterin APHENITY trial met primary endpoint; NDA filing planned Q4 2023.
GAAP net loss $198.9M; cash $337.9M; gene therapy discontinues caused $88M non-cash charge.
Full-year 2023 total revenue guidance raised to $940M-$1.0B; DMD product revenue guidance $545-$575M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PTC THERAPEUTICS, INC. reported financial results for the second quarter ending June 30, 2023.

Period: the second quarter ending June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.